Journal ArticleDOI
Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.
TLDR
There is enough published experience to suggest that TNF blockade represents an important therapeutic advancement for patients with severe and resistant, or intolerant, to standard immunosuppressive regimens BD.About:
This article is published in Seminars in Arthritis and Rheumatism.The article was published on 2011-08-01. It has received 285 citations till now. The article focuses on the topics: Infliximab & Adalimumab.read more
Citations
More filters
Journal ArticleDOI
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Grace A. Levy-Clarke,Douglas A. Jabs,Russell W. Read,James T. Rosenbaum,Albert T. Vitale,Russell N. Van Gelder +5 more
TL;DR: Infliximab and adalimumab can be considered as first-line immunomodulatory agents for the treatment of ocular manifestations of Behçet's disease and infliximab may be considered in these patients in preference to etanercept, which seems to be associated with lower rates of treatment success.
Journal ArticleDOI
Diagnosis and management of Neuro-Behcet's disease: international consensus recommendations.
Seema Kalra,Alan J. Silman,Gulsen Akman-Demir,Saeed Bohlega,Afshin Borhani-Haghighi,Cris S. Constantinescu,Habib Houman,Alfred Mahr,Carlo Salvarani,Petros P. Sfikakis,Aksel Siva,Adnan Al-Araji +11 more
TL;DR: This project developed expert consensus recommendations on consensus criteria for the diagnosis of NBD with two levels of certainty in addition to recommendations on when to consider NBD in a neurological patient, and on the use of various paraclinical tests.
Journal ArticleDOI
Small-vessel vasculitis.
TL;DR: Evaluation of a patient with suspected small‐vessel vasculitis requires skin biopsy, evaluation of the extent of the disease, and an attempt to define an etiology.
Journal ArticleDOI
Behçet's disease: New insights into pathophysiology, clinical features and treatment options.
Antonio Greco,Armando De Virgilio,Massimo Ralli,Andrea Ciofalo,Patrizia Mancini,Giuseppe Attanasio,Marco de Vincentiis,Alessandro Lambiase +7 more
TL;DR: Behçet's disease is a systemic vasculitis with significant neutrophil infiltration, endothelial cell swelling, and fibrinoid necrosis, and T cell homeostasis perturbation is supposed to be the cornerstone of BD pathogenesis.
Journal ArticleDOI
Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
TL;DR: Although monoclonal full IgG1 antibodies are able to induce clinical and endoscopic remission in inflammatory bowel diseases, certolizumab pegol without Fc portion has been shown to be less effective forinflammatory bowel diseases compared to full Igg1 antibodies.
References
More filters
Journal Article
Criteria for diagnosis of Behçet's disease
Journal ArticleDOI
The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center.
Emire Kural-Seyahi,Izzet Fresko,Nurhan Seyahi,Yilmaz Ozyazgan,Cem Mat,Vedat Hamuryudan,Sebahattin Yurdakul,H. Yazici +7 more
TL;DR: The results suggest that the “disease burden” of Behçet syndrome is usually confined to the early years of its course, and in many patients the syndrome “burns out.”
Journal ArticleDOI
EULAR recommendations for the management of Behçet disease
Gulen Hatemi,Alan J. Silman,Dongsik Bang,Bahram Bodaghi,A. M Chamberlain,Ahmet Gül,M. H Houman,Ina Kötter,I. Olivieri,Carlo Salvarani,Petros P. Sfikakis,Aksel Siva,Miles Stanford,N. Stübiger,Sebahattin Yurdakul,H. Yazici +15 more
TL;DR: Recommendations related to the eye, skin–mucosa disease and arthritis are mainly evidence based, but recommendations on vascular disease, neurological and gastrointestinal involvement are based largely on expert opinion and uncontrolled evidence from open trials and observational studies.
Journal ArticleDOI
Effect of infliximab on sight-threatening panuveitis in Behcet's disease
Petros P. Sfikakis,Panagiotis Theodossiadis,Christina G. Katsiari,Phaedon G. Kaklamanis,Nikos N. Markomichelakis +4 more
TL;DR: It is suggested that infliximab is a rapid and effective new therapy for sight-threatening ocular inflammation in Behçet's disease.
Journal Article
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Shigeaki Ohno,Satoshi Nakamura,Sadao Hori,Machiko Shimakawa,Hidetoshi Kawashima,Manabu Mochizuki,Sunao Sugita,Satoki Ueno,Kazuyuki Yoshizaki,Goro Inaba +9 more
TL;DR: Administration of infliximab in patients with Behçet's disease with refractory uveoretinitis suppressed the frequency of ocular attacks, and multiple administration was well tolerated, suggesting that inflIXimab is effective for this condition.